Nobuko Kuroishi

Ms. Nobuko Kuroishi

University of Miyazaki

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SAShinya Ashizuka
Shinya Ashizuka
NKNobuko Kuroishi
Nobuko Kuroishi
KNKoji Nakashima
Koji Nakashima
HIHaruhiko Inatsu
Haruhiko Inatsu
TKToshihiro Kita
Toshihiro Kita
KKKazuo Kitamura
Kazuo Kitamura
A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab therapy. A few days after, his symptoms went into remission. Endoscopy at 2 and 7 weeks revealed significant mucosal remission without steroid therapy. Adrenomedullin promoted mucosal healing and led to the re-induction of remission in Crohn's disease in a patient with a loss of response to infliximab.

19 July 2022 in Biology
Verified
Journal Article
Open access
PDF file
SNSayaka Nagata
Sayaka Nagata
MYMotoo Yamasaki
Motoo Yamasaki
NKNobuko Kuroishi
Nobuko Kuroishi
KKKazuo Kitamura
Kazuo Kitamura
(1) Background: Human adrenomedullin (hAM) is a hypotensive peptide hormone that exerts powerful anti-inflammatory effects. AM also had therapeutic effects in various animal experimental models of disease. However, treatment required continuous administration as the half-life of native AM is short in blood. To resolve this, we developed four human IgG1 and IgG4 Fc-fusion proteins containing full-length hAM or hAM residues 6-52. (2) Methods: We used mammalian cells to produce recombinant Fc-AM derivatives and tested the pharmacokinetics and biological activity of Fc-AM. (3) Results: We developed four Fc-fusion AMs (Fc-AM), which are long-acting AM derivatives in mammalian cells. Fc-AM had a prolonged half-life in blood and retained its ability to bind to the AM1 receptor. Fc-AM (6-52) induced higher cAMP levels for the receptor than Fc-AM. After the administration of IgG1-AM (6-52) or IgG4-AM (6-52) to rats, tissue transfer to the kidney and small intestine was observed. In addition, treatment with IgG4-AM (6-52) inhibited blood pressure increase in spontaneously hypertensive rats. (4) Conclusions: Fc-AM produced from mammalian cells can be easily prepared and might be an effective novel therapeutic agent.

7 October 2020 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
GMGoro Miki
Goro Miki
NKNobuko Kuroishi
Nobuko Kuroishi
MTMariko Tokashiki
Mariko Tokashiki
SNSayaka Nagata
Sayaka Nagata
MTMasaji Tamura
Masaji Tamura
KKKazuo Kitamura
Kazuo Kitamura
Human adrenomedullin (AM), a hypotensive peptide, also has anti-colitis activity. We prepared a polyethylene glycol (PEG) ylated form of AM through the conjugation of PEG-AM (1–15) and AM (15–52). Highly pure monomeric 20 kDa PEG-AM (20kPEG-AM) stimulated cyclic adenosine monophosphate production in HEK-293 cells stably expressing the type 1 AM receptor in a dose-dependent manner. The half-life of 20kPEG-AM was 7.4 h following subcutaneous administration in mice. We assessed the anti-colitis effect of subcutaneous 20kPEG-AM administration in the dextran sodium sulfate murine colitis model. Single and double subcutaneous injection of 20kPEG-AM significantly reduced total inflammation scores. These results suggest that 20kPEG-AM is a promising therapeutic candidate for the treatment of human inflammatory bowel diseases.